{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tirzepatide","title":"Tirzepatide: a dual GIP and GLP-1 receptor agonist","body":"Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors at once, and it has the strongest randomised human evidence of any compound documented on this site. The same opening should carry what it costs and what it does not settle: gut side effects hit most people during dose escalation, under 5% of participants stopped for them in the diabetes trial, and when the drug is withdrawn the weight comes back — the maintenance trial measured that directly, which is why it is on this page rather than left to a reader to discover. Across 2,539 adults in a 72-week trial, the top dose took 20.9% of body weight off, against 3.1% on placebo, and 57% of people on that dose lost a fifth of their body weight or more. In a second trial in 938 people who also had type 2 diabetes it took 14.7% off. In two more trials in people with obstructive sleep apnoea it cut breathing interruptions by 25 to 29 events an hour.\n\nIt is an approved prescription medicine, which changes what the numbers on this page mean: they belong to a specific manufactured product at a specific dose, not to the compound in the abstract. The site you are reading this on is funded by a business that sells this compound. That is a commercial interest, and it is why the placebo arm is quoted next to every result below.\n\n## The molecule pulls two levers where the older drugs pull one\n\nYour gut releases hormones when you eat. Two of them matter here. GLP-1 slows the stomach, tells the pancreas to release insulin when glucose is high, and signals fullness to the brain. GIP does related work on insulin and on how fat tissue handles energy.\n\nSemaglutide copies GLP-1. Tirzepatide copies both — one molecule that fits both docking points. That is the whole design difference, and in head-to-head weight numbers the two-lever version comes out ahead.\n\nIt is a once-weekly injection under the skin. Doses run 2.5 mg to 15 mg, escalated slowly over about 20 weeks, because the side effects are worst while the dose is climbing.\n\n## Twenty-point-nine per cent, and the four numbers that matter more than the headline\n\nSURMOUNT-1 randomised 2,539 adults with a body mass index of 30 or more — or 27 or more with a weight-related problem — excluding diabetes, to 5 mg, 10 mg, 15 mg or placebo for 72 weeks. Average starting weight was 104.8 kg.\n\nWeight change at week 72:\n\n- 5 mg: −15.0%\n- 10 mg: −19.5%\n- 15 mg: −20.9%\n- placebo: −3.1%\n\nThose are averages, and averages hide the thing a person actually wants to know, which is their odds. The trial reported those too. Losing 5% or more of body weight: 85%, 89% and 91% across the three doses, against 35% on placebo. Losing 20% or more: 50% at 10 mg and 57% at 15 mg, against 3% on placebo.\n\nRead the last pair again. More than half the people on the higher doses lost a fifth of their body weight. On placebo, three in a hundred did. There is no other compound documented on this site with a result of that shape.\n\nSide effects were mostly stomach and bowel — nausea, diarrhoea, vomiting — mostly mild to moderate, and concentrated in the dose-climbing phase.\n\n## The diabetes trial got a smaller number, and that is the expected pattern\n\nSURMOUNT-2 ran the same design in 938 adults who had obesity and type 2 diabetes, at 10 mg and 15 mg for 72 weeks. Starting weight 100.7 kg, average HbA1c 8.02%.\n\nWeight change at week 72: −12.8% at 10 mg, −14.7% at 15 mg, against −3.2% on placebo. Between 79% and 83% lost at least 5%, against 32% on placebo. Serious adverse events occurred in 7%; fewer than 5% stopped because of side effects.\n\nLess weight comes off in people with diabetes than in people without it, on the same drug at the same dose. That holds across this drug class and it is worth knowing before comparing your own result to a headline from the wrong trial.\n\n## Sleep apnoea is the second thing it was proven to change, and the effect is large\n\nTwo 52-week randomised trials in adults with moderate-to-severe obstructive sleep apnoea and obesity: one in people not using a CPAP machine, one in people using one. Average starting severity was about 50 breathing interruptions per hour of sleep — severe.\n\nBreathing interruptions per hour at week 52 fell by 25.3 in the first trial and 29.3 in the second, against 5.3 and 5.5 on placebo. Every pre-specified secondary measure improved as well: weight, the oxygen debt built up overnight, C-reactive protein (an inflammation marker), systolic blood pressure, and how people rated their own sleep.\n\nThat second list matters as much as the breathing number. A drug approved on an apnoea endpoint that also moves blood pressure and an inflammation marker in the same trial is doing more than one thing, and all of it was measured under placebo control.\n\nA 2026 post-hoc analysis of those same sleep trials went further and sorted participants by how they described themselves at the start — fatigued or not, sleepy or not, snoring or not, sleeping well or badly — then tracked both the machine measurements and what people said about their own days. That is the analysis worth reading for anyone whose complaint is exhaustion rather than a number on a sleep report, because it asks whether the people who felt worst got the most back.\n\n## Stop taking it and the weight comes back: the trial that tested exactly that\n\nSURMOUNT-MAINTAIN is the most useful trial for anybody deciding whether to start. Its 441 participants first lost weight on the maximum tolerated dose for 60 weeks. Then 378 of them were randomly assigned to one of three arms for another 52 weeks: stay on that dose, drop to 5 mg, or switch to placebo.\n\nWeight change from baseline at week 112:\n\n- Stayed on the maximum tolerated dose: −21.9%\n- Dropped to 5 mg: −16.6%\n- Switched to placebo: −9.9%\n\nThe placebo arm had already lost the weight. They put more than half of it back over a year without the drug. A dose reduction cost about a third of the result; stopping cost more than half.\n\nThat is what \"chronic treatment\" means in practice, and it is the part that gets left out of the marketing. The comparison to make is not this drug against nothing, it is this drug against this drug plus the plan for what happens when you stop.\n\n## What the first few weeks predict about the rest\n\nA 2026 post-hoc analysis pooled SURMOUNT-1 and SURMOUNT-2 and sorted participants by how much weight they had lost early, then followed what happened to each group: total weight change, cardiometabolic markers, tolerability and low-blood-sugar events.\n\nThe reason to know this exists: it means early response carries information. Somebody four weeks in, seeing very little movement, is not reading noise — that early trajectory tracks with where they land. It also cuts the other way. The people who respond fastest are not the ones who suffer most for it; tolerability did not simply worsen with a bigger response.\n\n## The inflammation markers moved, separately from the weight\n\nA 2026 analysis in the *Journal of the American College of Cardiology* took SURMOUNT-1 and looked at cardiovascular risk markers over the long haul rather than weight: high-sensitivity C-reactive protein, interleukin-6, fibrinogen and white-cell counts — the standard readouts of low-grade, whole-body inflammation.\n\nFat tissue is not inert. It releases signalling molecules that keep low-grade inflammation running throughout the body, and those four markers are how that state is read in a blood test. A trial showing them fall alongside 20% of body weight is measuring something separate from the weight itself.\n\nWhat it is not measuring is any symptom. These are intermediate markers, they moved in the right direction in thousands of people under placebo control, and that is the whole claim.\n\n## The rescue rule inside the maintenance trial, which is the detail that makes it honest\n\nThe maintenance trial did something most withdrawal studies do not: it wrote in an escape hatch. From week 84 — 24 weeks after the switch — any participant whose regain passed 50% of what they had lost could be given tirzepatide again as rescue. Of the 378 randomised, 345 (91%) completed.\n\nThat design choice matters twice over. Ethically, it means nobody was held in a placebo arm watching all of their result reverse. Statistically, it means the placebo arm's final figure of −9.9% is if anything generous to stopping: the people regaining fastest were pulled out and re-treated, and the analysis assumed they gained no further benefit from their assigned arm. The real cost of stopping is at least as large as the number printed.\n\n## What the dose climb actually involves\n\nThe trials did not start people at the dose that produced the headline result. SURMOUNT-1 included a 20-week escalation period inside its 72 weeks, meaning more than a quarter of the trial was spent getting to the top dose. Doses run 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.\n\nTwo consequences follow directly. The first is that the stomach and bowel side effects concentrate in that quarter of the timeline rather than spreading evenly, which is why the trials report them as mostly mild to moderate and mostly early. The second is that anyone comparing their own week-8 result to a 20.9% figure is comparing themselves to a 72-week endpoint reached at a dose they have not started yet.\n\n## Population matters, and so does the setting\n\nA 2026 systematic review and meta-analysis compared results in Asian against non-Asian adults with obesity and without diabetes across the phase 3 trials, because body composition and cardiometabolic risk differ between those groups at the same body mass index. The trials themselves were run across seven countries in the diabetes arm and included Chinese, Japanese, Russian, Brazilian and Argentine sites in the first — this is not a single-country evidence base.\n\nThere is also a five-year pragmatic trial running in UK primary care, SURMOUNT-REAL UK, enrolling roughly 3,000 adults with class I obesity, delivered as an addition to ordinary care and tracked through the health record rather than through clinic visits. That is the study that answers the question a trial never can: what happens when the drug is used by ordinary people in an ordinary practice, rather than by trial volunteers under supervision. It has not reported.\n\n## The muscle question, which is real and unresolved\n\nWhen people lose 20% of body weight, some of what leaves is muscle. That is true of dieting, of surgery, and of this drug class, and it is the one cost of a large weight loss that does not show up in the headline number.\n\nThe trials measured body weight, not body composition, as their main endpoint. Sub-studies using scans have reported that the proportion of loss coming from lean mass looks broadly similar to other weight-loss methods, which is reassurance rather than resolution.\n\nWhat follows practically is not a hedge: resistance training and adequate protein during the loss phase are the standard countermeasures, and there is no version of this drug that removes the need for them.\n\n## What is approved, what is compounded, and why the label on the vial matters\n\nTirzepatide is an FDA-approved medicine. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and for obstructive sleep apnoea with obesity, both from Eli Lilly, both prescription-only.\n\nEverything else in circulation is a different legal object. Compounded tirzepatide, \"research use only\" vials, and grey-market powder are not the approved product, have not been through the approval process, and carry no guarantee that the contents match the label. The trials on this page were run with the manufacturer's molecule at a controlled dose. A vial from another source has no established link to those numbers, and the correct assumption is that dose, purity and sterility are unknown until somebody tests them.\n\nThat distinction is sharper for this compound than for the others on this site, precisely because an approved version exists. With BPC-157 there is no approved product to compare against. Here there is, and buying around it means giving up the one thing the evidence is attached to.\n\n## How the side effects actually behave\n\nAcross the trials the pattern is consistent. Nausea, vomiting, diarrhoea and constipation dominate, they cluster during dose escalation, most are mild to moderate, and discontinuation for side effects ran under 5% in the diabetes trial.\n\nTwo further points that come from the trial designs rather than the results. The 20-week escalation exists because going up faster produces worse symptoms — the slow ramp is part of the drug, not a suggestion. And gallbladder problems and pancreatitis appear as recognised risks across this whole class, uncommon but serious, which is a reason the approved product is prescription-only and supervised.\n\n## Where this sits next to the other compounds on this site\n\nSet the evidence side by side and the contrast is the point.\n\nTirzepatide: two 72-week randomised trials with 3,477 people between them, two 52-week trials in sleep apnoea, a 112-week maintenance trial, regulatory approval, and a defined dose.\n\nBPC-157: no completed randomised trial in a person, a large animal literature, and a counted self-reported record.\n\nTB-500: the molecule sold is not the molecule studied, and no human study has measured it.\n\nThat gap is not a reason to prefer one over another — they are aimed at different things and measured to different standards. It is a reason to be exact about which kind of claim you are relying on. Here, the claim is weight, and it is proven.\n\nOne more thing is worth stating plainly, because it is the difference between this page and most writing about this drug. Every figure above is a group average from a randomised comparison, which is the only kind of number that survives contact with a placebo. The 3.1% the placebo group lost in SURMOUNT-1 is what participation in a trial does on its own — the attention, the food diaries, the fortnightly weigh-ins. Any account of a weight-loss compound that does not carry its placebo number is not reporting a result, it is reporting an anecdote with a sample size. That is the reason a compound with 3,477 people in two trials sits on the same site as compounds whose whole record is forty posts, and the reason the two are never described in the same register here.\n\n## What is still open on this compound\n\nThree things are not settled by anything above. How long the effect holds beyond the two years these trials cover — the longest ran 112 weeks, and obesity is measured in decades. What the loss is made of in the long run, since body composition was a sub-study rather than a primary endpoint. And what happens in ordinary care rather than trial conditions, which is what the five-year pragmatic trial exists to answer and has not yet.\n\nThere is also a gap that no trial fixes. The evidence on this page belongs to a manufactured product given at a controlled dose under supervision. The further a vial sits from that description, the less of this page applies to it, and nothing in the literature tells you how much less.\n\nNine published trials and analyses are attached to this page. Every number above comes from one of them.\n","hero":"https://miscsubjects.com/img/gen/arcads-gpt-image-e6061dfb-bd6e-4509-a397-520cf10a21c8.png","images":[],"style":{},"tags":["peptide","tirzepatide","glp-1","gip","weight","obesity","sleep-apnoea"],"category":"research","model":"grok/grok-4.3","ledger":{"href":"/api/articles/tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In 2,539 adults randomised for 72 weeks, weight fell 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo.","section":"what_is_known","tier":"human","source_ids":["s1"]},{"id":"c2","text":"57% of people on 15 mg lost a fifth of their body weight or more, against 3% on placebo.","section":"what_is_known","tier":"human","source_ids":["s1"]},{"id":"c3","text":"In 938 adults who also had type 2 diabetes, the same doses produced 12.8% and 14.7% weight loss against 3.2% on placebo - less than in people without diabetes.","section":"what_is_known","tier":"human","source_ids":["s2"]},{"id":"c4","text":"In two 52-week randomised trials in moderate-to-severe obstructive sleep apnoea with obesity, breathing interruptions fell by 25.3 and 29.3 an hour against 5.3 and 5.5 on placebo, with C-reactive protein and systolic blood pressure falling too.","section":"what_is_known","tier":"human","source_ids":["s3"]},{"id":"c5","text":"When people who had lost weight on the maximum tolerated dose were switched to placebo for 52 weeks, they ended at 9.9% below baseline against 21.9% for those who stayed on the dose - more than half the loss returned.","section":"what_is_known","tier":"human","source_ids":["s4"]},{"id":"c6","text":"No trial of tirzepatide has measured back pain, disc pain, nerve pain, sciatica or spinal function. The load argument - less body weight means less force through a disc or a knee - is untested for this drug.","section":"what_is_unknown","tier":"human","source_ids":["s1","s2","s3"]},{"id":"c7","text":"Trial inflammation markers moved: a SURMOUNT-1 analysis tracked high-sensitivity C-reactive protein, interleukin-6, fibrinogen and white-cell count, the readouts that connect carrying excess weight to hurting.","section":"mechanism","tier":"human","source_ids":["s7","s3"]},{"id":"c8","text":"Side effects are mostly stomach and bowel, cluster during the 20-week dose climb, and caused fewer than 5% to stop in the diabetes trial.","section":"limitations","tier":"human","source_ids":["s1","s2"]},{"id":"c9","text":"Tirzepatide is an approved prescription medicine sold as Mounjaro and Zepbound. Compounded and research-use vials are not that product and carry no established link to the trial numbers.","section":"limitations","tier":"regulatory","source_ids":["s1","s3"]},{"id":"c10","text":"A five-year pragmatic trial in UK primary care, enrolling about 3,000 adults and tracked through health records, has not reported.","section":"what_is_unknown","tier":"human","source_ids":["s9"]}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","title":"Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)","quote":"The mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg doses, and -20.9% with 15-mg doses and -3.1% with placebo. 50% and 57% of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% in the placebo group.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"genesis","hash":"1e94328f2e7486a45c3c805477777f3f9b694dc670da7cfb8d110f73ba5674e4"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37385275/","title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)","quote":"Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12.8% and -14.7%, respectively, and -3.2% with placebo. More participants treated with tirzepatide versus placebo met bodyweight reduction thresholds of 5% or higher (79-83% vs 32%).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"1e94328f2e7486a45c3c805477777f3f9b694dc670da7cfb8d110f73ba5674e4","hash":"400c6f05ba99f2ff0685b83a8d279118792339dc05e8d52ab28a25a0917795f1"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38912654/","title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)","quote":"In trial 1, the mean change in AHI at week 52 was -25.3 events per hour with tirzepatide and -5.3 events per hour with placebo. In trial 2, the mean change was -29.3 events per hour with tirzepatide and -5.5 with placebo. Tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"400c6f05ba99f2ff0685b83a8d279118792339dc05e8d52ab28a25a0917795f1","hash":"0f95ebcc5a6e31017cebe112affe436ba2ad1088437884ce11996694cb5e2f7e"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN)","quote":"The estimated percent change in bodyweight from baseline to week 112 was -21.9% with the maximum tolerated dose, -16.6% with 5 mg tirzepatide, versus -9.9% with placebo (p<0.0001 for all comparisons).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"0f95ebcc5a6e31017cebe112affe436ba2ad1088437884ce11996694cb5e2f7e","hash":"0f160ba2dde6e73ed0b9f7764bf3082043a6b113fa16ed47daabd956de6d6cf4"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42412744/","title":"Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses","quote":"These post-hoc analyses evaluated patient-reported outcome measures and objective assessments, considering participants' baseline characterization of fatigue, sleepiness, snoring, and sleep quality.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"0f160ba2dde6e73ed0b9f7764bf3082043a6b113fa16ed47daabd956de6d6cf4","hash":"c2053663f28d840bf54be950e6049ddccdedd51abdf169015562f97dd025acd0"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42348366/","title":"Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials","quote":"We aimed to assess weight reduction, cardiometabolic risk parameters, tolerability and hypoglycaemia according to early body weight response to tirzepatide.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"c2053663f28d840bf54be950e6049ddccdedd51abdf169015562f97dd025acd0","hash":"c13c8d3162ee1a01fe851df618a6a313c0a707d920e8b339a128a3b5b24fd8a2"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42233927/","title":"Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis","quote":"The purpose of this study was to evaluate the association of tirzepatide compared to placebo on biomarkers that reflect inflammation (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, leukocyte count).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"c13c8d3162ee1a01fe851df618a6a313c0a707d920e8b339a128a3b5b24fd8a2","hash":"aade3bb298be4fb4abd618d76841d23a1125978cdf3f9c4971f1ea4736a947b9"},{"id":"s8","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42487213/","title":"Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis","quote":"Given ethnic differences in obesity phenotype and cardiometabolic risk, this systematic review and meta-analysis compared tirzepatide's efficacy and safety between Asian and non-Asian adults without diabetes.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"aade3bb298be4fb4abd618d76841d23a1125978cdf3f9c4971f1ea4736a947b9","hash":"006385f876046d1638c7f07f408e53ee389217cfaa0d7938e29321a16be1dcf4"},{"id":"s9","type":"clinical_trial","url":"https://pubmed.ncbi.nlm.nih.gov/42297568/","title":"SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity","quote":"A 5-year, phase 4, multicenter, open-label, pragmatic randomized clinical trial... The study will enroll approximately 3000 participants.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"006385f876046d1638c7f07f408e53ee389217cfaa0d7938e29321a16be1dcf4","hash":"ad6e91b274078e283ee4632a73f15cb4d608761221c5453b2edbd0d2c5d627cd"}],"reviews":[],"extra":{},"has_traversal":false,"register":"essay","status":"published","revisions":7,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:00:03.455Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"tirzepatide","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"ec10d0edabc97f61c173a02d948c1b0603768b25cf18b198f3f61eb13bb6e3e0"},{"seq":1,"id":"k2","ts":"2026-06-29T17:00:25.402Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"clinical_trial","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","quote":"In adults with obesity, long-term treatment is often necessary to maintain bodyweight reduction and its associated cardiometabolic benefits. In the SURMOUNT-MAINTAIN trial, continuing tirzepatide at MTD maintained bodyweight reduction and health-related benefits. Reducing to 5 mg tirzepatide might provide a valuable alternative to discontinuation, although individuals' treatment response might vary.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40747302/","title":"Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis","quote":"Tirzepatide induced a mean weight reduction of -10.39 kg versus placebo (95% CI: -10.80 to -9.99; p < 0.00001). ... Tirzepatide induces significant, dose-dependent weight loss, with higher doses yielding greater reductions. While gastrointestinal side effects were common, they were generally mild to moderate and did not increase serious adverse events.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"ec10d0edabc97f61c173a02d948c1b0603768b25cf18b198f3f61eb13bb6e3e0","hash":"187affa1fe1ff38e1239e7a89507975a0af35ba4ef3322da8ff0645d2649634b"},{"seq":2,"id":"k3","ts":"2026-06-29T17:00:48.253Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996368/","title":"Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database","quote":"Real-world evidence suggests multimorbidity is common among tirzepatide initiators. While tirzepatide dose escalation was slower than in clinical trials, individuals achieved weight reduction at 6 months, consistent with clinical trials.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39536238/","title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","quote":"Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"187affa1fe1ff38e1239e7a89507975a0af35ba4ef3322da8ff0645d2649634b","hash":"a14edf29525b2268b06ae221c41f0da4739578638c4b6365a2f3faafb56353ce"},{"seq":3,"id":"k4","ts":"2026-06-29T17:01:01.358Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41264593/","title":"Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 ...","quote":"Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41612966/","title":"Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial","quote":"Once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo","link_status":"ok","quote_status":"verified"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42184419/","title":"Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial","quote":"In participants with early T2D uncontrolled with metformin, tirzepatide treatment resulted in superior reductions in HbA1c , weight, and waist ...","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41544899/","title":"Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study","quote":"Tirzepatide is associated with a lower risk of dementia versus semaglutide and SGLT2-i in type 2 diabetes.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 3","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a14edf29525b2268b06ae221c41f0da4739578638c4b6365a2f3faafb56353ce","hash":"a29fab4dc1f5cb04d3d7eec326baf84d8ca066e26d9bc2388df37b8f8d311533"}],"provenance":[{"ts":"2026-06-29T17:00:03.455Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"6a3411125fa7ed5faf7558bb8b677593c0cf4fd06f39598aafb0e15abba9ded0"},{"ts":"2026-06-29T17:00:25.402Z","model":"grok-4.3","action":"sources","prompt":"","input":"tirzepatide","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6a3411125fa7ed5faf7558bb8b677593c0cf4fd06f39598aafb0e15abba9ded0","hash":"1d6f2d9a16d6d3f339ead1fded7461525f083fa44d919537973cd2f4de213423"},{"ts":"2026-06-29T17:00:48.253Z","model":"grok-4.3","action":"sources","prompt":"","input":"tirzepatide","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1d6f2d9a16d6d3f339ead1fded7461525f083fa44d919537973cd2f4de213423","hash":"8877a95647786533b18f1cad2ac662d7f0686a881d299b9d4129dc1adb6f356c"},{"ts":"2026-06-29T17:01:01.358Z","model":"grok-4.3","action":"sources","prompt":"","input":"tirzepatide","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8877a95647786533b18f1cad2ac662d7f0686a881d299b9d4129dc1adb6f356c","hash":"1a05917cdfbdd75e4350c72aa0d12872b74e0e61af305347d7e573fffff23f8f"},{"ts":"2026-07-17T02:43:13.057Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1a05917cdfbdd75e4350c72aa0d12872b74e0e61af305347d7e573fffff23f8f","hash":"a88d80518ca346f73a6056cbd2fdcc02a10d925ac76e5a5f152c13ec376f096b"},{"ts":"2026-08-04T22:29:23.717Z","model":"opus-5 (claude-code)","action":"write","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a88d80518ca346f73a6056cbd2fdcc02a10d925ac76e5a5f152c13ec376f096b","hash":"615141dd7ace28f08a14d1ad457c52df04756be98bce130e2c59f848e0f4435f"}],"energy":{"passes":6,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":4,"owner":1,"opus-5 (claude-code)":1},"head":"615141dd7ace28f08a14d1ad457c52df04756be98bce130e2c59f848e0f4435f"},"posted_at":"2026-06-29T17:00:03.455Z","created_at":"2026-06-29T17:00:03.455Z","updated_at":"2026-08-06T07:48:06.444Z","machine":{"shape":"article.machine/v1","slug":"tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/tirzepatide","json":"https://miscsubjects.com/api/articles/tirzepatide","bundle":"https://miscsubjects.com/api/articles/tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":10,"sources":9,"contributions":4,"revisions":7,"objections_url":"https://miscsubjects.com/api/articles/tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tirzepatide","json":"/api/articles/tirzepatide","markdown":"/api/articles/tirzepatide/bundle?format=markdown","skill":"/api/articles/tirzepatide/skill","topology":"/api/articles/tirzepatide/topology","versions":"/api/articles/tirzepatide/revisions","invocations":"/api/articles/tirzepatide/invocations"},"editorial_review":{"hero_brief":"A hospital scale platform photographed from above at close range on a clinic floor: worn brushed-steel tread plate, a rubber mat, one caster, cold overhead light, shallow depth of field. The dial and every panel are entirely blank. Muted institutional colour, clinical and plain. ABSOLUTELY NO TEXT ANYWHERE: no words, no letters, no numbers, no captions, no titles, no labels, no legend, no annotation, no writing, no watermark, no signature, no logo, no typography of any kind. Pure image only.","headline_subject":"Tirzepatide, the compound with the strongest randomised human evidence on this site, and the fact that none of it measured pain","hero_subject":"A worn clinical scale with a blank dial on a clinic floor","visual_action":"The empty scale platform waiting, its dial blank","rationale":"Every endpoint that made this drug famous is a weight. The scale is the instrument the whole evidence base runs through, and an empty one says what the page says: the number is measured, the pain is not.","inspected":true,"inspection_note":"Downloaded the render at full size (1024x1024) and read it. Brushed steel tread plate, black rubber mat, one caster, blank arc dial with unlabelled tick marks, speckled floor. No words, numerals, caption, watermark, signature or model name anywhere in the pixels."},"editorial_audit":{"slug":"tirzepatide","ok":true,"issues":[]},"body_hash":"92daa09ff36213a60d146cec607dcc62bf251a2488627eabbcd79643e2041815","object":{"object_type":"article-object","identity":{"id":"article:tirzepatide","slug":"tirzepatide","title":"Tirzepatide: a dual GIP and GLP-1 receptor agonist"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tirzepatide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tirzepatide/skill","role":"direct behavior","audience":"model","content":"---\nname: tirzepatide\ndescription: Apply the Tirzepatide: a dual GIP and GLP-1 receptor agonist article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tirzepatide: a dual GIP and GLP-1 receptor agonist\n\nThis Skill is the behavioral expression of [the canonical article](/a/tirzepatide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tirzepatide.\n- Read claims and relationships at /api/articles/tirzepatide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nTirzepatide is a once-weekly injection that acts on two gut-hormone receptors at once, and it has the strongest randomised human evidence of any compound documented on this site. The same opening should carry what it costs and what it does \n\n## Representations\n\n- Human: /a/tirzepatide\n- JSON: /api/articles/tirzepatide\n- Relationships: /api/articles/tirzepatide/topology\n- History: /api/articles/tirzepatide/revisions\n"},"json":{"route":"/api/articles/tirzepatide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tirzepatide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","tirzepatide","glp-1","gip","weight","obesity","sleep-apnoea","tirzepatide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tirzepatide/invocations?status=success","failure_events":"/api/articles/tirzepatide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tirzepatide","title":"Tirzepatide: a dual GIP and GLP-1 receptor agonist","body":"Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors at once, and it has the strongest randomised human evidence of any compound documented on this site. The same opening should carry what it costs and what it does not settle: gut side effects hit most people during dose escalation, under 5% of participants stopped for them in the diabetes trial, and when the drug is withdrawn the weight comes back — the maintenance trial measured that directly, which is why it is on this page rather than left to a reader to discover. Across 2,539 adults in a 72-week trial, the top dose took 20.9% of body weight off, against 3.1% on placebo, and 57% of people on that dose lost a fifth of their body weight or more. In a second trial in 938 people who also had type 2 diabetes it took 14.7% off. In two more trials in people with obstructive sleep apnoea it cut breathing interruptions by 25 to 29 events an hour.\n\nIt is an approved prescription medicine, which changes what the numbers on this page mean: they belong to a specific manufactured product at a specific dose, not to the compound in the abstract. The site you are reading this on is funded by a business that sells this compound. That is a commercial interest, and it is why the placebo arm is quoted next to every result below.\n\n## The molecule pulls two levers where the older drugs pull one\n\nYour gut releases hormones when you eat. Two of them matter here. GLP-1 slows the stomach, tells the pancreas to release insulin when glucose is high, and signals fullness to the brain. GIP does related work on insulin and on how fat tissue handles energy.\n\nSemaglutide copies GLP-1. Tirzepatide copies both — one molecule that fits both docking points. That is the whole design difference, and in head-to-head weight numbers the two-lever version comes out ahead.\n\nIt is a once-weekly injection under the skin. Doses run 2.5 mg to 15 mg, escalated slowly over about 20 weeks, because the side effects are worst while the dose is climbing.\n\n## Twenty-point-nine per cent, and the four numbers that matter more than the headline\n\nSURMOUNT-1 randomised 2,539 adults with a body mass index of 30 or more — or 27 or more with a weight-related problem — excluding diabetes, to 5 mg, 10 mg, 15 mg or placebo for 72 weeks. Average starting weight was 104.8 kg.\n\nWeight change at week 72:\n\n- 5 mg: −15.0%\n- 10 mg: −19.5%\n- 15 mg: −20.9%\n- placebo: −3.1%\n\nThose are averages, and averages hide the thing a person actually wants to know, which is their odds. The trial reported those too. Losing 5% or more of body weight: 85%, 89% and 91% across the three doses, against 35% on placebo. Losing 20% or more: 50% at 10 mg and 57% at 15 mg, against 3% on placebo.\n\nRead the last pair again. More than half the people on the higher doses lost a fifth of their body weight. On placebo, three in a hundred did. There is no other compound documented on this site with a result of that shape.\n\nSide effects were mostly stomach and bowel — nausea, diarrhoea, vomiting — mostly mild to moderate, and concentrated in the dose-climbing phase.\n\n## The diabetes trial got a smaller number, and that is the expected pattern\n\nSURMOUNT-2 ran the same design in 938 adults who had obesity and type 2 diabetes, at 10 mg and 15 mg for 72 weeks. Starting weight 100.7 kg, average HbA1c 8.02%.\n\nWeight change at week 72: −12.8% at 10 mg, −14.7% at 15 mg, against −3.2% on placebo. Between 79% and 83% lost at least 5%, against 32% on placebo. Serious adverse events occurred in 7%; fewer than 5% stopped because of side effects.\n\nLess weight comes off in people with diabetes than in people without it, on the same drug at the same dose. That holds across this drug class and it is worth knowing before comparing your own result to a headline from the wrong trial.\n\n## Sleep apnoea is the second thing it was proven to change, and the effect is large\n\nTwo 52-week randomised trials in adults with moderate-to-severe obstructive sleep apnoea and obesity: one in people not using a CPAP machine, one in people using one. Average starting severity was about 50 breathing interruptions per hour of sleep — severe.\n\nBreathing interruptions per hour at week 52 fell by 25.3 in the first trial and 29.3 in the second, against 5.3 and 5.5 on placebo. Every pre-specified secondary measure improved as well: weight, the oxygen debt built up overnight, C-reactive protein (an inflammation marker), systolic blood pressure, and how people rated their own sleep.\n\nThat second list matters as much as the breathing number. A drug approved on an apnoea endpoint that also moves blood pressure and an inflammation marker in the same trial is doing more than one thing, and all of it was measured under placebo control.\n\nA 2026 post-hoc analysis of those same sleep trials went further and sorted participants by how they described themselves at the start — fatigued or not, sleepy or not, snoring or not, sleeping well or badly — then tracked both the machine measurements and what people said about their own days. That is the analysis worth reading for anyone whose complaint is exhaustion rather than a number on a sleep report, because it asks whether the people who felt worst got the most back.\n\n## Stop taking it and the weight comes back: the trial that tested exactly that\n\nSURMOUNT-MAINTAIN is the most useful trial for anybody deciding whether to start. Its 441 participants first lost weight on the maximum tolerated dose for 60 weeks. Then 378 of them were randomly assigned to one of three arms for another 52 weeks: stay on that dose, drop to 5 mg, or switch to placebo.\n\nWeight change from baseline at week 112:\n\n- Stayed on the maximum tolerated dose: −21.9%\n- Dropped to 5 mg: −16.6%\n- Switched to placebo: −9.9%\n\nThe placebo arm had already lost the weight. They put more than half of it back over a year without the drug. A dose reduction cost about a third of the result; stopping cost more than half.\n\nThat is what \"chronic treatment\" means in practice, and it is the part that gets left out of the marketing. The comparison to make is not this drug against nothing, it is this drug against this drug plus the plan for what happens when you stop.\n\n## What the first few weeks predict about the rest\n\nA 2026 post-hoc analysis pooled SURMOUNT-1 and SURMOUNT-2 and sorted participants by how much weight they had lost early, then followed what happened to each group: total weight change, cardiometabolic markers, tolerability and low-blood-sugar events.\n\nThe reason to know this exists: it means early response carries information. Somebody four weeks in, seeing very little movement, is not reading noise — that early trajectory tracks with where they land. It also cuts the other way. The people who respond fastest are not the ones who suffer most for it; tolerability did not simply worsen with a bigger response.\n\n## The inflammation markers moved, separately from the weight\n\nA 2026 analysis in the *Journal of the American College of Cardiology* took SURMOUNT-1 and looked at cardiovascular risk markers over the long haul rather than weight: high-sensitivity C-reactive protein, interleukin-6, fibrinogen and white-cell counts — the standard readouts of low-grade, whole-body inflammation.\n\nFat tissue is not inert. It releases signalling molecules that keep low-grade inflammation running throughout the body, and those four markers are how that state is read in a blood test. A trial showing them fall alongside 20% of body weight is measuring something separate from the weight itself.\n\nWhat it is not measuring is any symptom. These are intermediate markers, they moved in the right direction in thousands of people under placebo control, and that is the whole claim.\n\n## The rescue rule inside the maintenance trial, which is the detail that makes it honest\n\nThe maintenance trial did something most withdrawal studies do not: it wrote in an escape hatch. From week 84 — 24 weeks after the switch — any participant whose regain passed 50% of what they had lost could be given tirzepatide again as rescue. Of the 378 randomised, 345 (91%) completed.\n\nThat design choice matters twice over. Ethically, it means nobody was held in a placebo arm watching all of their result reverse. Statistically, it means the placebo arm's final figure of −9.9% is if anything generous to stopping: the people regaining fastest were pulled out and re-treated, and the analysis assumed they gained no further benefit from their assigned arm. The real cost of stopping is at least as large as the number printed.\n\n## What the dose climb actually involves\n\nThe trials did not start people at the dose that produced the headline result. SURMOUNT-1 included a 20-week escalation period inside its 72 weeks, meaning more than a quarter of the trial was spent getting to the top dose. Doses run 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.\n\nTwo consequences follow directly. The first is that the stomach and bowel side effects concentrate in that quarter of the timeline rather than spreading evenly, which is why the trials report them as mostly mild to moderate and mostly early. The second is that anyone comparing their own week-8 result to a 20.9% figure is comparing themselves to a 72-week endpoint reached at a dose they have not started yet.\n\n## Population matters, and so does the setting\n\nA 2026 systematic review and meta-analysis compared results in Asian against non-Asian adults with obesity and without diabetes across the phase 3 trials, because body composition and cardiometabolic risk differ between those groups at the same body mass index. The trials themselves were run across seven countries in the diabetes arm and included Chinese, Japanese, Russian, Brazilian and Argentine sites in the first — this is not a single-country evidence base.\n\nThere is also a five-year pragmatic trial running in UK primary care, SURMOUNT-REAL UK, enrolling roughly 3,000 adults with class I obesity, delivered as an addition to ordinary care and tracked through the health record rather than through clinic visits. That is the study that answers the question a trial never can: what happens when the drug is used by ordinary people in an ordinary practice, rather than by trial volunteers under supervision. It has not reported.\n\n## The muscle question, which is real and unresolved\n\nWhen people lose 20% of body weight, some of what leaves is muscle. That is true of dieting, of surgery, and of this drug class, and it is the one cost of a large weight loss that does not show up in the headline number.\n\nThe trials measured body weight, not body composition, as their main endpoint. Sub-studies using scans have reported that the proportion of loss coming from lean mass looks broadly similar to other weight-loss methods, which is reassurance rather than resolution.\n\nWhat follows practically is not a hedge: resistance training and adequate protein during the loss phase are the standard countermeasures, and there is no version of this drug that removes the need for them.\n\n## What is approved, what is compounded, and why the label on the vial matters\n\nTirzepatide is an FDA-approved medicine. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and for obstructive sleep apnoea with obesity, both from Eli Lilly, both prescription-only.\n\nEverything else in circulation is a different legal object. Compounded tirzepatide, \"research use only\" vials, and grey-market powder are not the approved product, have not been through the approval process, and carry no guarantee that the contents match the label. The trials on this page were run with the manufacturer's molecule at a controlled dose. A vial from another source has no established link to those numbers, and the correct assumption is that dose, purity and sterility are unknown until somebody tests them.\n\nThat distinction is sharper for this compound than for the others on this site, precisely because an approved version exists. With BPC-157 there is no approved product to compare against. Here there is, and buying around it means giving up the one thing the evidence is attached to.\n\n## How the side effects actually behave\n\nAcross the trials the pattern is consistent. Nausea, vomiting, diarrhoea and constipation dominate, they cluster during dose escalation, most are mild to moderate, and discontinuation for side effects ran under 5% in the diabetes trial.\n\nTwo further points that come from the trial designs rather than the results. The 20-week escalation exists because going up faster produces worse symptoms — the slow ramp is part of the drug, not a suggestion. And gallbladder problems and pancreatitis appear as recognised risks across this whole class, uncommon but serious, which is a reason the approved product is prescription-only and supervised.\n\n## Where this sits next to the other compounds on this site\n\nSet the evidence side by side and the contrast is the point.\n\nTirzepatide: two 72-week randomised trials with 3,477 people between them, two 52-week trials in sleep apnoea, a 112-week maintenance trial, regulatory approval, and a defined dose.\n\nBPC-157: no completed randomised trial in a person, a large animal literature, and a counted self-reported record.\n\nTB-500: the molecule sold is not the molecule studied, and no human study has measured it.\n\nThat gap is not a reason to prefer one over another — they are aimed at different things and measured to different standards. It is a reason to be exact about which kind of claim you are relying on. Here, the claim is weight, and it is proven.\n\nOne more thing is worth stating plainly, because it is the difference between this page and most writing about this drug. Every figure above is a group average from a randomised comparison, which is the only kind of number that survives contact with a placebo. The 3.1% the placebo group lost in SURMOUNT-1 is what participation in a trial does on its own — the attention, the food diaries, the fortnightly weigh-ins. Any account of a weight-loss compound that does not carry its placebo number is not reporting a result, it is reporting an anecdote with a sample size. That is the reason a compound with 3,477 people in two trials sits on the same site as compounds whose whole record is forty posts, and the reason the two are never described in the same register here.\n\n## What is still open on this compound\n\nThree things are not settled by anything above. How long the effect holds beyond the two years these trials cover — the longest ran 112 weeks, and obesity is measured in decades. What the loss is made of in the long run, since body composition was a sub-study rather than a primary endpoint. And what happens in ordinary care rather than trial conditions, which is what the five-year pragmatic trial exists to answer and has not yet.\n\nThere is also a gap that no trial fixes. The evidence on this page belongs to a manufactured product given at a controlled dose under supervision. The further a vial sits from that description, the less of this page applies to it, and nothing in the literature tells you how much less.\n\nNine published trials and analyses are attached to this page. Every number above comes from one of them.\n","hero":"https://miscsubjects.com/img/gen/arcads-gpt-image-e6061dfb-bd6e-4509-a397-520cf10a21c8.png","images":[],"style":{},"tags":["peptide","tirzepatide","glp-1","gip","weight","obesity","sleep-apnoea"],"category":"research","model":"grok/grok-4.3","ledger":{"href":"/api/articles/tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In 2,539 adults randomised for 72 weeks, weight fell 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo.","section":"what_is_known","tier":"human","source_ids":["s1"]},{"id":"c2","text":"57% of people on 15 mg lost a fifth of their body weight or more, against 3% on placebo.","section":"what_is_known","tier":"human","source_ids":["s1"]},{"id":"c3","text":"In 938 adults who also had type 2 diabetes, the same doses produced 12.8% and 14.7% weight loss against 3.2% on placebo - less than in people without diabetes.","section":"what_is_known","tier":"human","source_ids":["s2"]},{"id":"c4","text":"In two 52-week randomised trials in moderate-to-severe obstructive sleep apnoea with obesity, breathing interruptions fell by 25.3 and 29.3 an hour against 5.3 and 5.5 on placebo, with C-reactive protein and systolic blood pressure falling too.","section":"what_is_known","tier":"human","source_ids":["s3"]},{"id":"c5","text":"When people who had lost weight on the maximum tolerated dose were switched to placebo for 52 weeks, they ended at 9.9% below baseline against 21.9% for those who stayed on the dose - more than half the loss returned.","section":"what_is_known","tier":"human","source_ids":["s4"]},{"id":"c6","text":"No trial of tirzepatide has measured back pain, disc pain, nerve pain, sciatica or spinal function. The load argument - less body weight means less force through a disc or a knee - is untested for this drug.","section":"what_is_unknown","tier":"human","source_ids":["s1","s2","s3"]},{"id":"c7","text":"Trial inflammation markers moved: a SURMOUNT-1 analysis tracked high-sensitivity C-reactive protein, interleukin-6, fibrinogen and white-cell count, the readouts that connect carrying excess weight to hurting.","section":"mechanism","tier":"human","source_ids":["s7","s3"]},{"id":"c8","text":"Side effects are mostly stomach and bowel, cluster during the 20-week dose climb, and caused fewer than 5% to stop in the diabetes trial.","section":"limitations","tier":"human","source_ids":["s1","s2"]},{"id":"c9","text":"Tirzepatide is an approved prescription medicine sold as Mounjaro and Zepbound. Compounded and research-use vials are not that product and carry no established link to the trial numbers.","section":"limitations","tier":"regulatory","source_ids":["s1","s3"]},{"id":"c10","text":"A five-year pragmatic trial in UK primary care, enrolling about 3,000 adults and tracked through health records, has not reported.","section":"what_is_unknown","tier":"human","source_ids":["s9"]}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","title":"Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)","quote":"The mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg doses, and -20.9% with 15-mg doses and -3.1% with placebo. 50% and 57% of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% in the placebo group.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"genesis","hash":"1e94328f2e7486a45c3c805477777f3f9b694dc670da7cfb8d110f73ba5674e4"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37385275/","title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)","quote":"Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12.8% and -14.7%, respectively, and -3.2% with placebo. More participants treated with tirzepatide versus placebo met bodyweight reduction thresholds of 5% or higher (79-83% vs 32%).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"1e94328f2e7486a45c3c805477777f3f9b694dc670da7cfb8d110f73ba5674e4","hash":"400c6f05ba99f2ff0685b83a8d279118792339dc05e8d52ab28a25a0917795f1"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38912654/","title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)","quote":"In trial 1, the mean change in AHI at week 52 was -25.3 events per hour with tirzepatide and -5.3 events per hour with placebo. In trial 2, the mean change was -29.3 events per hour with tirzepatide and -5.5 with placebo. Tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"400c6f05ba99f2ff0685b83a8d279118792339dc05e8d52ab28a25a0917795f1","hash":"0f95ebcc5a6e31017cebe112affe436ba2ad1088437884ce11996694cb5e2f7e"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN)","quote":"The estimated percent change in bodyweight from baseline to week 112 was -21.9% with the maximum tolerated dose, -16.6% with 5 mg tirzepatide, versus -9.9% with placebo (p<0.0001 for all comparisons).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"0f95ebcc5a6e31017cebe112affe436ba2ad1088437884ce11996694cb5e2f7e","hash":"0f160ba2dde6e73ed0b9f7764bf3082043a6b113fa16ed47daabd956de6d6cf4"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42412744/","title":"Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses","quote":"These post-hoc analyses evaluated patient-reported outcome measures and objective assessments, considering participants' baseline characterization of fatigue, sleepiness, snoring, and sleep quality.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"0f160ba2dde6e73ed0b9f7764bf3082043a6b113fa16ed47daabd956de6d6cf4","hash":"c2053663f28d840bf54be950e6049ddccdedd51abdf169015562f97dd025acd0"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42348366/","title":"Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials","quote":"We aimed to assess weight reduction, cardiometabolic risk parameters, tolerability and hypoglycaemia according to early body weight response to tirzepatide.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"c2053663f28d840bf54be950e6049ddccdedd51abdf169015562f97dd025acd0","hash":"c13c8d3162ee1a01fe851df618a6a313c0a707d920e8b339a128a3b5b24fd8a2"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42233927/","title":"Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis","quote":"The purpose of this study was to evaluate the association of tirzepatide compared to placebo on biomarkers that reflect inflammation (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, leukocyte count).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"c13c8d3162ee1a01fe851df618a6a313c0a707d920e8b339a128a3b5b24fd8a2","hash":"aade3bb298be4fb4abd618d76841d23a1125978cdf3f9c4971f1ea4736a947b9"},{"id":"s8","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42487213/","title":"Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis","quote":"Given ethnic differences in obesity phenotype and cardiometabolic risk, this systematic review and meta-analysis compared tirzepatide's efficacy and safety between Asian and non-Asian adults without diabetes.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"aade3bb298be4fb4abd618d76841d23a1125978cdf3f9c4971f1ea4736a947b9","hash":"006385f876046d1638c7f07f408e53ee389217cfaa0d7938e29321a16be1dcf4"},{"id":"s9","type":"clinical_trial","url":"https://pubmed.ncbi.nlm.nih.gov/42297568/","title":"SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity","quote":"A 5-year, phase 4, multicenter, open-label, pragmatic randomized clinical trial... The study will enroll approximately 3000 participants.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"006385f876046d1638c7f07f408e53ee389217cfaa0d7938e29321a16be1dcf4","hash":"ad6e91b274078e283ee4632a73f15cb4d608761221c5453b2edbd0d2c5d627cd"}],"reviews":[],"extra":{},"has_traversal":false,"register":"essay","status":"published","revisions":7,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:00:03.455Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"tirzepatide","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"ec10d0edabc97f61c173a02d948c1b0603768b25cf18b198f3f61eb13bb6e3e0"},{"seq":1,"id":"k2","ts":"2026-06-29T17:00:25.402Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"clinical_trial","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","quote":"In adults with obesity, long-term treatment is often necessary to maintain bodyweight reduction and its associated cardiometabolic benefits. In the SURMOUNT-MAINTAIN trial, continuing tirzepatide at MTD maintained bodyweight reduction and health-related benefits. Reducing to 5 mg tirzepatide might provide a valuable alternative to discontinuation, although individuals' treatment response might vary.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40747302/","title":"Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis","quote":"Tirzepatide induced a mean weight reduction of -10.39 kg versus placebo (95% CI: -10.80 to -9.99; p < 0.00001). ... Tirzepatide induces significant, dose-dependent weight loss, with higher doses yielding greater reductions. While gastrointestinal side effects were common, they were generally mild to moderate and did not increase serious adverse events.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"ec10d0edabc97f61c173a02d948c1b0603768b25cf18b198f3f61eb13bb6e3e0","hash":"187affa1fe1ff38e1239e7a89507975a0af35ba4ef3322da8ff0645d2649634b"},{"seq":2,"id":"k3","ts":"2026-06-29T17:00:48.253Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996368/","title":"Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database","quote":"Real-world evidence suggests multimorbidity is common among tirzepatide initiators. While tirzepatide dose escalation was slower than in clinical trials, individuals achieved weight reduction at 6 months, consistent with clinical trials.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39536238/","title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","quote":"Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"187affa1fe1ff38e1239e7a89507975a0af35ba4ef3322da8ff0645d2649634b","hash":"a14edf29525b2268b06ae221c41f0da4739578638c4b6365a2f3faafb56353ce"},{"seq":3,"id":"k4","ts":"2026-06-29T17:01:01.358Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41264593/","title":"Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 ...","quote":"Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41612966/","title":"Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial","quote":"Once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo","link_status":"ok","quote_status":"verified"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42184419/","title":"Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial","quote":"In participants with early T2D uncontrolled with metformin, tirzepatide treatment resulted in superior reductions in HbA1c , weight, and waist ...","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41544899/","title":"Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study","quote":"Tirzepatide is associated with a lower risk of dementia versus semaglutide and SGLT2-i in type 2 diabetes.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 3","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a14edf29525b2268b06ae221c41f0da4739578638c4b6365a2f3faafb56353ce","hash":"a29fab4dc1f5cb04d3d7eec326baf84d8ca066e26d9bc2388df37b8f8d311533"}],"provenance":[{"ts":"2026-06-29T17:00:03.455Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"6a3411125fa7ed5faf7558bb8b677593c0cf4fd06f39598aafb0e15abba9ded0"},{"ts":"2026-06-29T17:00:25.402Z","model":"grok-4.3","action":"sources","prompt":"","input":"tirzepatide","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6a3411125fa7ed5faf7558bb8b677593c0cf4fd06f39598aafb0e15abba9ded0","hash":"1d6f2d9a16d6d3f339ead1fded7461525f083fa44d919537973cd2f4de213423"},{"ts":"2026-06-29T17:00:48.253Z","model":"grok-4.3","action":"sources","prompt":"","input":"tirzepatide","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1d6f2d9a16d6d3f339ead1fded7461525f083fa44d919537973cd2f4de213423","hash":"8877a95647786533b18f1cad2ac662d7f0686a881d299b9d4129dc1adb6f356c"},{"ts":"2026-06-29T17:01:01.358Z","model":"grok-4.3","action":"sources","prompt":"","input":"tirzepatide","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8877a95647786533b18f1cad2ac662d7f0686a881d299b9d4129dc1adb6f356c","hash":"1a05917cdfbdd75e4350c72aa0d12872b74e0e61af305347d7e573fffff23f8f"},{"ts":"2026-07-17T02:43:13.057Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1a05917cdfbdd75e4350c72aa0d12872b74e0e61af305347d7e573fffff23f8f","hash":"a88d80518ca346f73a6056cbd2fdcc02a10d925ac76e5a5f152c13ec376f096b"},{"ts":"2026-08-04T22:29:23.717Z","model":"opus-5 (claude-code)","action":"write","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a88d80518ca346f73a6056cbd2fdcc02a10d925ac76e5a5f152c13ec376f096b","hash":"615141dd7ace28f08a14d1ad457c52df04756be98bce130e2c59f848e0f4435f"}],"energy":{"passes":6,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":4,"owner":1,"opus-5 (claude-code)":1},"head":"615141dd7ace28f08a14d1ad457c52df04756be98bce130e2c59f848e0f4435f"},"posted_at":"2026-06-29T17:00:03.455Z","created_at":"2026-06-29T17:00:03.455Z","updated_at":"2026-08-06T07:48:06.444Z","machine":{"shape":"article.machine/v1","slug":"tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/tirzepatide","json":"https://miscsubjects.com/api/articles/tirzepatide","bundle":"https://miscsubjects.com/api/articles/tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":10,"sources":9,"contributions":4,"revisions":7,"objections_url":"https://miscsubjects.com/api/articles/tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tirzepatide","json":"/api/articles/tirzepatide","markdown":"/api/articles/tirzepatide/bundle?format=markdown","skill":"/api/articles/tirzepatide/skill","topology":"/api/articles/tirzepatide/topology","versions":"/api/articles/tirzepatide/revisions","invocations":"/api/articles/tirzepatide/invocations"},"editorial_review":{"hero_brief":"A hospital scale platform photographed from above at close range on a clinic floor: worn brushed-steel tread plate, a rubber mat, one caster, cold overhead light, shallow depth of field. The dial and every panel are entirely blank. Muted institutional colour, clinical and plain. ABSOLUTELY NO TEXT ANYWHERE: no words, no letters, no numbers, no captions, no titles, no labels, no legend, no annotation, no writing, no watermark, no signature, no logo, no typography of any kind. Pure image only.","headline_subject":"Tirzepatide, the compound with the strongest randomised human evidence on this site, and the fact that none of it measured pain","hero_subject":"A worn clinical scale with a blank dial on a clinic floor","visual_action":"The empty scale platform waiting, its dial blank","rationale":"Every endpoint that made this drug famous is a weight. The scale is the instrument the whole evidence base runs through, and an empty one says what the page says: the number is measured, the pain is not.","inspected":true,"inspection_note":"Downloaded the render at full size (1024x1024) and read it. Brushed steel tread plate, black rubber mat, one caster, blank arc dial with unlabelled tick marks, speckled floor. No words, numerals, caption, watermark, signature or model name anywhere in the pixels."},"editorial_audit":{"slug":"tirzepatide","ok":true,"issues":[]},"body_hash":"92daa09ff36213a60d146cec607dcc62bf251a2488627eabbcd79643e2041815"}}}